louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04397952: Endotracheal Tube Cuff Pressure Measurement
Official title: Comparison of Two Different Measurement of Endotracheal Tube Cuff Pressure for Ventilatory Associated Pnemonia in Severe Brain Injured Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ventilator Associated Pneumonia
Morality
Trauma, Brain
Endotracheal Aspiration
Keywords: pneumonia, cuff pressure, brain injury
Lead sponsor: Bagcilar Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2020-05-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who followed up in a tertiary intensive care unit diagnosed with traumatic brain injury and under mechanical ventilation.

Brief summary: The effect of endotracheal cuff pressure measurement technique for preventing ventilatory associated pneumonia.

Detailed description: Aim of this study is to evaluate the effect of endotracheal cuff pressure measurement technique for preventing ventilatory associated pneumonia of severe traumatic brain injured patients in a tertiary level intensive care unit.

Eligibility criteria: Inclusion Criteria:

Patients with ASA classification of 1 - 2- 3 patients Patients required mechanical ventilation support for more than 48 hours Patients diagnosed with Traumatic brain injury

Exclusion Criteria:

Official patient relatives who rejected to give informed consent for the study Patients diagnosed with aspiration pneumonia during ICU follow up Patients diagnosed with Acute Respiratory Distress Syndrome Patients diagnosed with cavitary lung lesion Primary lung cancer Metastatic lung cancer Congenitally immune deficiency Leukopenia Neutropenia Tracheostomized patients Post cardiopulmonary arrest patients Pregnancy

Primary outcomes:
measure: Duration
timeFrame: 30 days
measure: Ventilation
timeFrame: 30 days
measure: Score
timeFrame: 48.hour - 72.hour - 96.hour
measure: CRP
timeFrame: 48.hour - 72.hour - 96.hour
measure: Oxygenation
timeFrame: 48.hour - 72.hour - 96.hour
measure: PEEP
timeFrame: 48.hour - 72.hour - 96.hour
Secondary outcomes:
measure: Tracheal aspirate
timeFrame: 0.hour - 48.hour - 72.hour - 96.hour
measure: Bacterial distribution
timeFrame: 0.hour - 48.hour - 72.hour - 96.hour
measure: Mortality
timeFrame: 30 days
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bagcilar Training and Research Hospital
Study officials:
affiliation: Univesity of Health Sciences Bagcilar Training and Research Hospital
name: Salih SS Sevdi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01012752: A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
Official title: A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Allergic Rhinitis
Allergic Conjunctivitis
Lead sponsor: Roxall Medizin
Sponsor class: INDUSTRY
First posted: 2009-11-13
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is performed to evaluate the safety and clinical efficacy of subcutaneous specific immunotherapy in patients suffering from seasonal allergic rhinitis/rhinoconjunctivitis.


Eligibility criteria: Inclusion Criteria:

* Positive history of allergen specific allergic rhinitis/rhinoconjunctivitis
* Positive screening skin prick test (wheal diameter \> 3 mm)
* Compliance and ability of the patient to complete a Diary Card for self-evaluating of the symptoms and antisymptomatic medication
* Signed and dated patient´s Informed Consent,

Exclusion Criteria:

* Previous immunotherapy within the last 3 years,
* Simultaneous participation in other clinical trials,
* Other reasons contra-indicating an inclusion into the trial according to the investigator´s estimation (e.g. poor compliance),
* Auto-immune disorders,
* Severe chronic inflammatory diseases,
* Malignancy,
* Alcohol abuse,
* Existing or intended pregnancy, lactation and/or lack of adequate contraceptive protection,
* Treatment with beta-blockers (incl. local application) and/or other contra-indicated drugs.

Primary outcomes:
measure: Symptom and medication score
timeFrame: 1 year
Secondary outcomes:
measure: Safety of the treatment
timeFrame: 1 year
measure: Documentation of adverse events
timeFrame: 1 year
measure: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
timeFrame: 1 year
measure: Clinical global improvement
timeFrame: 1 year
Other outcomes:
Locations:
city: Hamburg
country: Germany
Study officials:
References:
Clinical trial NCT06585852: Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement
Official title: Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement. A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Implant Dentistry
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to evaluate the efficacy of xenograft alone or xenograft mixed with Arginylglycylaspartic acid (RGD) , in horizontal ridge augmentation with split-crest technique, for implant placement.

Detailed description: A comparative study for ridge augmentation procedure, With two groups. First group underwent a surgical ridge splitting procedure with ultrasonic bone surgery and grafting with Xenograft alone and implant placement. Second group underwent a surgical ridge splitting procedure with ultrasonic bone surgery Xenograft mix ed with Arginylglycylaspartic acid (RGD) and implant placement.

Both groups were followed up for 1 and 3 months after loading.

Eligibility criteria: Inclusion Criteria:

1. Adults (age 18-30) exhibiting initial insufficiently bone width.
2. Patients with good oral hygiene.
3. Patients must be free from systemic diseases that may influence the outcome of the therapy.
4. Patients with bony horizontal defects alone, Class III \& IV.

Exclusion Criteria:

1. Heavy smokers.
2. Patient treated by immunosuppressive chemotherapy or radio therapy,
3. Allergy to any material or medication used in the study.
4. Pregnant females.

Primary outcomes:
measure: ISQ measurement for implant stability
timeFrame: At time of surgery, at loading and 3 months after loading.
Secondary outcomes:
measure: Bone density around dental implants.
timeFrame: At time of loading and 3 months after loading
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al Azhar University of Cairo
state: Nasr City
Study officials:
References:
Clinical trial NCT06381752: Value of Continuous Passive Motion in Rehabilitation After Total Knee Replacement
Official title: Value of Continuous Passive Motion in Rehabilitation After Total Knee Replacement - A Prospective Randomized Controlled Multicenter Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Total Knee Arthroplasty
Keywords: CPM
inpatient rehabilitation
Staffelstein Score
Lead sponsor: Johannes Gutenberg University Mainz
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 175
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Immediate rehabilitation after total knee arthroplasty (TKA) differs in terms of volume, intensity but also type of treatment. Continuous passive motion after TKA is so far only investigated for replacing physiotherapy. This study is conducted to investigate CPM when it partially replaces group physiotherapy in terms of functional and patient-reported outcomes.

Detailed description: The aim of this study is to analyze the value (knee function, pain, and quality of life) of continuous passive motion (CPM) after total knee replacement (TKR), when it partially replaces group physiotherapy (PT) in inpatient rehabilitation to save human resources. Patients are randomized to CPM group, consisting of 3 daily sessions of 20 minutes each, or to group PT, consisting of 25 minutes physiotherapy in groups 5 days weekly. Multimodal rehabilitation does not differ for both groups throughout the 3-week rehabilitation stay.

Primary outcome is the Staffelstein Score, German standard score in rehabilitation. Secondary outcomes are Oxford Knee Score (OKS), active and passive range of motion (ROM), and pain on visual analogue scale (VAS). Return to work is assessed by post-operative days.

Eligibility criteria: Inclusion Criteria:

* Total knee arthroplasty because of knee osteoarthritis
* Inpatient rehabilitation in participating clinics

Exclusion Criteria:

* Pregnancy
* Not able to give informed consent
* Psychological disorders
* Body weight \&gt; 150 kg
* Hip range of motion \&lt; 50°

Primary outcomes:
measure: Staffelstein Score
timeFrame: baseline (t0) and 3 weeks later (t1)
Secondary outcomes:
measure: Oxford Knee Score (OKS)
timeFrame: baseline (t0), 10 days after baseline (t1), 3 weeks after baseline (t2), 4 months after baseline (t3)
measure: Range of motion (ROM)
timeFrame: baseline (t0), 10 days after baseline (t1), 3 weeks after baseline
measure: Visual Analogue Scale (VAS)
timeFrame: baseline (t0), 10 days after baseline (t1), 3 weeks after baseline (t2)
measure: Return to work
timeFrame: baseline (t0), 4 months after baseline (t3)
Other outcomes:
Locations:
city: Mainz
country: Germany
facility: Universitaetsmedizin der JGU Mainz
state: Rheinland-Pfalz
Study officials:
References:
Clinical trial NCT01320852: PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)
Official title: PET Scan as a Screening Tool for Liver Transplant in Patients With HCC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Keywords: Transplant
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2011-03-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: This study aims at testing the utility of PET Scan as a screening tool for liver transplantation in patients with Hepatocellular Carcinoma. Patients being worked up for liver transplant for hepatocellular carcinoma will undergo a PET Scan and will be followed until 2 years after transplantation. At that time survival data will be analysed according to PET Scan results to determine if it can be used to predict outcome.


Eligibility criteria: Inclusion Criteria:

* Male or female patient over 18 years of age
* Diagnosis of HCC confirmed by histology if available or by two imaging modalities
* Able to give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.

Exclusion Criteria:

* Unable to give consent to the study
* Unable to undergo a PET Scan

Primary outcomes:
measure: Overall Survival
timeFrame: up to death
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: McGill Univeristy Health Centre
state: Quebec
Study officials:
References:
Clinical trial NCT00768352: Educational Intervention for Optimizing Adolescent Mental Health Screening and Treatment in Pediatric Residency
Official title: An Educational Intervention for Optimizing Adolescent Mental Health Screening Skills and Treatment in Pediatric Residency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mental Health
Keywords: Pediatric
Resident
Depression
Screening
Substance Abuse
Pediatric Resident knowledge of mental health topics
Pediatric Resident current practices for screening and treating mental health disorders
Pediatric Resident mental health care competency
Lead sponsor: Brooke Army Medical Center
Sponsor class: FED
First posted: 2008-10-08
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of this study is: 1) to assess pediatric resident knowledge of adolescent mental health; 2) to assess pediatric resident comfort level for screening, assessing, and treating mental health disorders in adolescents, and; 3) to evaluate pediatric resident current practices for adolescent mental health screening, assessment, and treatment.


Eligibility criteria: Inclusion Criteria:

* Pediatric Residents
* Adolescent Rotation

Exclusion Criteria:

* None

Primary outcomes:
measure: Do pediatric residents lack an adequate knowledge base for screening, assessing, and treating mental health disorders in adolescents?
timeFrame: Feb 2008-June 2009
Secondary outcomes:
measure: Are pediatric residents are comfortable with screening, assessing, and treating adolescent mental health disorders. Do pediatric residents use validated verbal or written mental health screening and assessment tools.
timeFrame: Feb 2008-June 2009
Other outcomes:
Locations:
city: Ft Sam Houston
country: United States
facility: Brooke Army medical Center
state: Texas
Study officials:
References:
Clinical trial NCT05158452: Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer
Official title: Development of a Genetic Counseling Patient Preference Intervention for Women at Elevated Risk for Breast Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Carcinoma
Lead sponsor: Ohio State University Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2021-12-15
Enrollment: 8
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women at elevated risk for breast cancer

Brief summary: This study develops a genetic counseling patient preference intervention for women at elevated risk for breast cancer. This study aims to develop an intervention that may deliver educational videos about breast cancer, heredity, multigene tests results and polygenic risk score, provide multigene and polygenic test results, obtain information about patients' questions/ concerns about test results to use in post-genetic test counseling, and determine patient preference (e.g. telephone) for receipt of post-genetic test counseling.

Detailed description: PRIMARY OBJECTIVE:

I. Develop the Genetic Counseling Patient Preference (GCPP) intervention in collaboration with community members.

OUTLINE:

Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.

Eligibility criteria: Inclusion Criteria:

* Female
* Ages 35-64
* Known elevated risk for breast cancer
* The ability to speak and read English
* Provide written consent

Primary outcomes:
measure: Development of Genetic Counseling Patient Preference (GCPP) intervention
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Ohio State University Comprehensive Cancer Center
state: Ohio
Study officials:
affiliation: Ohio State University Comprehensive Cancer Center
name: Kevin Sweet, MS, LGC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04485052: Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Official title: A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2020-07-24
Enrollment: 222
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia


Eligibility criteria: Inclusion Criteria:

1. AML patients diagnosed according to WHO AML diagnostic criteria in 2016 (except M3-type and BCR-ABL positive AML).
2. Relapsed// refractory AML( ≥18 ys) or newly diagnosed elderly AML unfit for intensive chemotherapy( ≥60 ys).
3. Age ≥18 years old, gender not limited.
4. ECOG score of 0-2.
5. Adequate organ function.

Exclusion Criteria:

1. Acute promyelocytic leukemia, myeloid sarcoma, acute heterozygous leukemia, CMML(accelerated phase and blast phase).
2. A history of myeloproliferative diseases (including myelofibrosis, primary thrombocytosis, and true red) Cytosis, chronic myelocytic leukemia) or acute myeloid white blood with BCR-ABL1 translocation Patients.
3. Major surgery and vaccine treatment within 4 weeks.
4. Uncontrolled concurrent diseases.
5. Pregnant or breastfeeding female subjects.

Primary outcomes:
measure: Composite complete rate
timeFrame: 24 weeks
Secondary outcomes:
measure: Cytogenetic CR
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
References:
Clinical trial NCT04799652: Are Surgeons Ready to Get the COVID-19 Vaccine?
Official title: Are Surgeons Ready to Get the COVID-19 Vaccine?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Lead sponsor: Brugmann University Hospital
Sponsor class: OTHER
First posted: 2021-03-16
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Physicians affiliated to Belgian Hospitals

Brief summary: The COVID-19 pandemic continues to rage and most of the world is facing a second wave with continuous lockdown and strict measures aiming to control it. While vaccination is on its way, and has even started in several countries, trust and acceptance remain a challenge for an effective vaccination strategy, especially with the increasing vaccination hesitance in recent years . It is important to understand the main concerns towards the COVID-19 vaccine so they can be addressed in a constructive way - more specifically among health care professionals who are at the frontline of the pandemic.

The aim of this study is to evaluate whether surgeons are ready for the COVID-19 vaccine and to understand their main concerns towards the vaccine.

In an objective to evaluate the attitude of doctors towards the COVID vaccine and the effect of prolonged lockdown on their psychological burden, the investigators created an anonymous survey of 21 questions.


Eligibility criteria: Inclusion Criteria:

* Physicians affiliated to Belgian Hospitals

Exclusion Criteria:

* None

Primary outcomes:
measure: Perception and knowledge towards the vaccine
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHU Brugmann
Study officials:
affiliation: CHU Brugmann
name: Yasser Farid
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03169452: Clinical Application and Outcome of Non-invasive Ventilation in Different Chest Diseases
Official title: Clinical Application and Outcome of Non-invasive Ventilation in Different Chest Diseases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chest--Diseases
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-30
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who admitted to the Respiratory intensive care unit and the attending team conducted him to Non invasive ventilation

Brief summary: Noninvasive ventilation is increasingly used method of respiratory management in both the emergency room and critical care. Noninvasive ventilation delivers mechanically assisted breaths without the placement of an artificial airway and has become an important mechanism of ventilator support inside and outside the intensive care unit.

Noninvasive ventilation is further subdivided into negative pressure ventilation which is the iron lung, first used in 1928 and the Hayek oscillator, is a more recently designed to provide negative pressure during inspiration and positive pressure during expiration. Noninvasive positive pressure ventilation can be used as continuous positive airway pressure or bi-level positive airway pressure.


Eligibility criteria: Inclusion Criteria:

* obstructive sleep apnea syndrome
* acute exacerbation Chronic obstructive pulmonary disease
* pneumonia
* interstitial lung diseases

Exclusion Criteria:

* Patients refuse Non invasive ventilation
* Patients with absolute indication for Mechanical ventilator (in respiratory arrest or unstable cardiorespiratory status, trauma or burns involving the face, or gastric surgery, reduced consciousness, Pneumothorax
* Patients with contraindication to Non invasive ventilation

Primary outcomes:
measure: percentage of patients need mechanical ventilation
timeFrame: 1-48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References: